119.94
1.99%
-2.44
After Hours:
119.94
Biontech Se Adr Stock (BNTX) Latest News
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - GlobeNewswire Inc.
BioNTech SE ADR (BNTX) did well last session? - US Post News
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales - Yahoo Finance
Moderna and BioNTech shares fall after Senate committee vote on RFK Jr. - Investing.com
Hesai Group ADR (HSAI) shows promising results - US Post News
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings? - Yahoo Finance
Validea Benjamin Graham Strategy Daily Upgrade Report1/31/2025 - Nasdaq
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Stocks To Watch: BioNTech ADR Sees Relative Strength Rating Rise To 84 - Inkl
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know - MSN
Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading - Snopes.com
BioNTech Expands Cancer Drug Pipeline: Launches Key Lung Cancer Trials, Advances Immunotherapy Programs - StockTitan
Why BioNTech (BNTX) Shares Are Volatile TodayBioNTech (NASDAQ:BNTX) - Benzinga
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
What’s Behind The Recent Rise In MRNA Stock? - Forbes
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike - Investor's Business Daily
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BNTX: 3 Genomic Stocks Unlocking the Secrets of DNA - StockNews.com
BioNTech SE ADR rises Friday, still underperforms market - MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
Russia develops mRNA cancer vaccine for citizens, skepticism lingers - Mugglehead
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR falls Thursday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, still underperforms market - MarketWatch
BioNTech SE ADR rises Monday, still underperforms market - MarketWatch
Stocks Generating Improved Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech's SWOT analysis: mRNA pioneer's stock faces oncology pipeline test - Investing.com
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock balances COVID legacy, oncology future - Investing.com
Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily
BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech's SWOT analysis: oncology pipeline fuels stock's potential amid market volatility - Investing.com
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):